The global neurological biomarkers market grew at a CAGR of around 15% during 2015-2020. Looking forward, IMARC Group expects the market to exhibit strong growth during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end-use sectors. These insights are included in the report as a major market contributor.

Neurological biomarkers are molecules present in the blood or cerebral spinal fluid (CSF) that support the diagnosis of brain disorders and monitor disease progression. The main sources of these biomarkers are genetic mutations, metabolite levels, brain imaging and changes in protein expression or post-translational modifications. As they detect biological responses to experimental drugs and aid in discovering new targets for therapeutic intervention, neurological biomarkers are widely used in clinical practice during drug development. Presently, researchers measure biomarker concentrations to provide non-invasive testing, earlier diagnosis and personalized treatments.
The rising occurrence of neurological disorders, such as stroke, motor neuron disease (MND), Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD), is escalating the need for faster drug development. This represents one of the primary factors impelling the market growth as biomarkers help measure the efficacy of new drugs and therapeutic strategies. The increasing adoption of minimally invasive procedures and personalized medicines are acting as another major growth-inducing factor. Apart from this, as various neurological disorders share standard features, there is an increase in the demand for multiple biomarkers to differentiate specific diseases and their sub-types. Moreover, advancements in mass spectrometry and imaging procedures enable faster evaluation of large numbers of biochemical markers and structural changes in the brain. This, along with the introduction of digital biomarkers and the rising number of clinical trials, is anticipated to propel the growth of the market in the coming years.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global neurological biomarkers market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, type, application and end use.

Breakup by Type:

Genomic Biomarkers
Proteomic Biomarkers
Metabolomic Biomarkers
Imaging Biomarkers
Others

Breakup by Application:

Alzheimer’s Disease
Parkinson’s Disease
Multiple Sclerosis
Autism Spectrum Disorders
Others

Breakup by End Use:

Hospital Laboratories
Clinical Diagnostic Centers
Research Organizations
Others

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Acumen Pharmaceuticals Inc., Athena Diagnostics (Quest Diagnostics), Banyan Biomarkers Inc., Bio-Rad Laboratories Inc., Immunarray Pvt. Ltd., Myriad Rbm, Inc. (Myriad Genetics Inc.), Proteome Sciences Plc and Thermo Fisher Scientific Inc.

Key questions answered in this report:
How has the global neurological biomarkers market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global neurological biomarkers market?
What are the key regional markets?
What is the breakup of the market based on the type?
What is the breakup of the market based on the application?
What is the breakup of the market based on the end use?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global neurological biomarkers market and who are the key players?
What is the degree of competition in the industry?